In a prospective study with postmenopausal patients, Baumgart et al. found no significant difference in urinary incontinence symptoms between breast cancer patients treated with tamoxifen or aromatase inhibitors and a healthy control group [9]. Here, CYP19A1 is linked to breast cancer.